Latest KFF Health News Stories
Is Novavax, the Latecomer Covid Vaccine, Worth the Wait?
People with special medical considerations are hoping the Novavax shot will bring fewer headaches, fevers, and less fatigue than have been reported by those taking mRNA vaccines.
Doubts Abound About a New Alzheimer’s Blood Test
Quest Diagnostics is selling a blood test online to consumers. But results may not be reliable or easy to interpret. And it isn’t covered by insurance.
California Moves Ahead of the FDA in Banning Common Candy Additives
The legislation bans the use of four additives that are already prohibited in many other countries but remain in popular U.S. foods. Advocates say states need to act because the FDA has done little.
PrEP, a Key HIV Prevention Tool, Isn’t Reaching Black Women
New HIV infections occur disproportionately among Black women, but exclusionary marketing, fewer treatment options, and provider wariness have limited uptake of preexposure prophylaxis, or PrEP, drugs, which reduce the risk of contracting the virus.
Thousands Got Exactech Knee or Hip Replacements. Then, Patients Say, the Parts Began to Fail.
In a torrent of lawsuits, patients accuse Florida device maker Exactech of hiding knee and hip implant defects for years. The company denies the allegations.
KFF Health News' 'What the Health?': Underinsured Is the New Uninsured
The percentage of working-age adults with health insurance went up and the uninsured rate dropped last year, the U.S. Census Bureau reported this week. There isn’t much suspense about which way the uninsured rate is now trending, as states continue efforts to strip ineligible beneficiaries from their Medicaid rolls. But is the focus on the uninsured obscuring the struggles of the underinsured? Margot Sanger-Katz of The New York Times, Sarah Karlin-Smith of the Pink Sheet, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Emmarie Huetteman to discuss these issues and more.
Por qué los CDC recomiendan el nuevo refuerzo contra covid para todos
El Comité Asesor sobre Prácticas de Inmunización de los CDC votó 13-1 a favor de la moción después de meses de debate sobre si limitar los refuerzos a grupos de alto riesgo.
Why the CDC Has Recommended New Covid Boosters for All
As covid-19 hospitalizations tick upward with fall approaching, the CDC says it’s time for new boosters — and not only for those at highest risk of serious disease. Here are seven things you need to know.
A Nanoengineer Teamed Up With Rihanna’s Tattoo Artist to Make Smarter Ink
Tattoos are more popular than ever. About a third of Americans have at least one. A scientist-entrepreneur, together with a celebrity tattoo artist, believes that ink could be doing a lot more.
Mujeres negras sopesan riesgos emergentes de alisadores para el cabello “adictivos”
Los alisadores pueden contener carcinógenos, como agentes liberadores de formaldehído, ftalatos y otros compuestos que alteran el sistema endócrino, según estudios de los Institutos Nacionales de Salud.
Black Women Weigh Emerging Risks of ‘Creamy Crack’ Hair Straighteners
Social and economic pressures have long compelled Black girls and women to straighten their hair. But mounting evidence shows chemical straighteners — products with little regulatory oversight — may pose cancer and other health risks.
FDA Head Robert Califf Battles Misinformation — Sometimes With Fuzzy Facts
FDA Commissioner Robert Califf has called misinformation one of the deadliest killers in the United States. As the FDA tries to fight that scourge, it sometimes stumbles.
¿Cuánto costará la píldora anticonceptiva de venta libre? ¿La cubrirán los seguros?
Los defensores de la salud reproductiva celebraron esta histórica aprobación como un paso que puede ayudar a millones de personas a evitar embarazos no deseados, que ocurren casi la mitad de las veces en los Estados Unidos.
Once the New Over-the-Counter Birth Control Pill Is Available, What About Cost and Coverage?
The Food and Drug Administration’s approval is viewed as groundbreaking, but many details still must be figured out.
KFF Health News' 'What the Health?': The Long Road to Reining In Short-Term Plans
President Biden made good on a campaign promise this week with a proposal that would limit short-term health insurance plans that boast low premiums but also few benefits. Meanwhile, the Supreme Court’s decision to outlaw affirmative action programs could set back efforts to diversify the nation’s medical workforce. Alice Miranda Ollstein of Politico, Amy Goldstein of the Washington Post, and Rachel Cohrs of Stat News join KFF Health News’ chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Bram Sable-Smith, who reported the latest KFF Health News-NPR “Bill of the Month” about how a hospital couldn’t track down a patient, but a debt collector could.
As Low-Nicotine Cigarettes Hit the Market, Anti-Smoking Groups Press for Wider Standard
The first FDA-authorized cigarettes with 95% less nicotine than traditional smokes will go on sale in California, Florida, and Texas starting in early July. Anti-smoking groups oppose greenlighting just one plant biotech’s products and instead urge federal regulators to set a low-nicotine standard for the entire industry.
Más adolescentes adictos a cigarrillos electrónicos con altas dosis de nicotina
El vapeo se ha disparado hasta convertirse en una industria de $8.2 mil millones, y los fabricantes están inundando el mercado con miles de productos que pueden ser mucho más adictivos.
E-Cigs Are Still Flooding the US, Addicting Teens With Higher Nicotine Doses
The FDA, Justice Department, and White House have failed to act as vapes with kid-friendly flavors like cotton candy or gummy bears proliferate.
El cisplatino y el carboplatino son algunos de los medicamentos que escasean, así como otros 12 contra el cáncer, pastillas para el trastorno por déficit de atención con hiperactividad, anticoagulantes y antibióticos.
Drugmakers Are Abandoning Cheap Generics, and Now US Cancer Patients Can’t Get Meds
A quality-control crisis at an Indian pharmaceutical factory has left doctors and their patients with impossible choices as cheap, effective, generic cancer drugs go out of stock.
